NBC Securities Inc. bought a new stake in shares of AbCellera Biologics Inc. (NASDAQ:ABCL – Free Report) in the third quarter, Holdings Channel reports. The fund bought 6,720 shares of the company’s stock, valued at approximately $30,000.
Several other large investors also recently bought and sold shares of ABCL. Worth Asset Management LLC acquired a new stake in AbCellera Biologics during the 1st quarter worth approximately $25,000. Point72 Asset Management L.P. purchased a new position in shares of AbCellera Biologics in the second quarter valued at $26,000. National Bank of Canada FI increased its holdings in shares of AbCellera Biologics by 392.7% in the 3rd quarter. National Bank of Canada FI now owns 6,085 shares of the company’s stock worth $27,000 after acquiring an additional 4,850 shares during the period. Point72 Middle East FZE acquired a new position in AbCellera Biologics during the 2nd quarter valued at about $30,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of AbCellera Biologics by 96.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,423 shares of the company’s stock worth $34,000 after purchasing an additional 3,638 shares during the period. Hedge funds and other institutional investors own 47.39% of the company’s stock.
AbCellera Biologics Stock Up 2.2 %
Shares of AbCellera Biologics stock opened at $5.02 on Friday. The business has a 50-day moving average price of $5.34 and a 200 day moving average price of $5.19. The firm has a market cap of $1.46 billion, a P/E ratio of -11.16 and a beta of 0.38. AbCellera Biologics Inc. has a fifty-two week low of $3.87 and a fifty-two week high of $10.59.
Analyst Ratings Changes
AbCellera Biologics Company Profile
AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets.
- Five stocks we like better than AbCellera Biologics
- Where to Find Earnings Call Transcripts
- The 5 best small cap AI companies to buy now
- Consumer Discretionary Stocks Explained
- Cirrus Logic: A chip stock you’re going to hear a lot more about
- Overbought Stocks Explained: Should You Trade Them?
- Archer Aviation’s sky-high progress and short interest
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.